• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An Open Question: Is the A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?

作者信息

Merighi Stefania, Poloni Tino Emanuele, Pelloni Lucia, Pasquini Silvia, Varani Katia, Vincenzi Fabrizio, Borea Pier Andrea, Gessi Stefania

机构信息

Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy.

Department of Neurology and Neuropathology, Golgi-Cenci Foundation and ASP Golgi-Redaelli, Abbiategrasso, Italy.

出版信息

Front Pharmacol. 2021 Mar 22;12:652455. doi: 10.3389/fphar.2021.652455. eCollection 2021.

DOI:10.3389/fphar.2021.652455
PMID:33828485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8019913/
Abstract
摘要

相似文献

1
An Open Question: Is the A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?一个悬而未决的问题：A1腺苷受体是阿尔茨海默病治疗的新靶点吗？
Front Pharmacol. 2021 Mar 22;12:652455. doi: 10.3389/fphar.2021.652455. eCollection 2021.
2
A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease.腺苷受体作为阿尔茨海默病的潜在生物标志物和可能的治疗靶点。
Cells. 2021 Sep 7;10(9):2344. doi: 10.3390/cells10092344.
3
A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?腺苷受体：通过调节 NLRP3 炎症小体活性治疗阿尔茨海默病的可能靶点？
Int J Mol Sci. 2022 May 2;23(9):5056. doi: 10.3390/ijms23095056.
4
A Adenosine Receptor Antagonists and their Potential in Neurological Disorders.腺苷受体拮抗剂及其在神经紊乱中的潜在应用。
Curr Med Chem. 2022 Aug 6;29(28):4780-4795. doi: 10.2174/0929867329666220218094501.
5
Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease.皮质 A2A 腺苷受体的上调反映在阿尔茨海默病患者的血小板中。
J Alzheimers Dis. 2021;80(3):1105-1117. doi: 10.3233/JAD-201437.
6
A Adenosine Receptor Antagonists in Neurodegenerative Diseases.腺嘌呤受体拮抗剂在神经退行性疾病中的应用。
Curr Med Chem. 2022;29(24):4138-4151. doi: 10.2174/0929867328666211129122550.
7
Pathophysiological Role and Medicinal Chemistry of A Adenosine Receptor Antagonists in Alzheimer's Disease.A 腺苷受体拮抗剂在阿尔茨海默病中的病理生理作用和药物化学。
Molecules. 2022 Apr 21;27(9):2680. doi: 10.3390/molecules27092680.
8
Caffeine for Prevention of Alzheimer's Disease: Is the A Adenosine Receptor Its Target?咖啡因预防阿尔茨海默病：A 腺苷受体是其靶点吗？
Biomolecules. 2023 Jun 8;13(6):967. doi: 10.3390/biom13060967.
9
5-Substituted 2-benzylidene-1-tetralone analogues as A and/or A antagonists for the potential treatment of neurological conditions.5-取代的2-亚苄基-1-四氢萘酮类似物作为A和/或A拮抗剂用于潜在治疗神经疾病。
Bioorg Chem. 2017 Oct;74:251-259. doi: 10.1016/j.bioorg.2017.08.013. Epub 2017 Aug 30.
10
Molecular and Structural Insight into Adenosine A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach.分子与结构视角下神经退行性疾病中的腺苷 A 受体：高效治疗方法的重要靶点。
Mol Neurobiol. 2023 Oct;60(10):5987-6000. doi: 10.1007/s12035-023-03441-5. Epub 2023 Jun 30.

引用本文的文献

1
Experimental modeling of Alzheimer's disease: Translational lessons from cross-taxon analyses.阿尔茨海默病的实验模型：跨分类分析的转化经验教训。
Alzheimers Dement. 2025 May;21(5):e70273. doi: 10.1002/alz.70273.
2
Alterations in the Processing of Platelet APP (Amyloid Beta Precursor Protein) in Alzheimer Disease: The Possible Nexus.阿尔茨海默病中血小板淀粉样前体蛋白（APP）加工过程的改变：可能的联系
Neuropsychopharmacol Rep. 2025 Mar;45(1):e12525. doi: 10.1002/npr2.12525.
3
A adenosine receptor agonists, antagonists, inverse agonists and partial agonists.腺嘌呤核苷受体激动剂、拮抗剂、反向激动剂和部分激动剂。
Int Rev Neurobiol. 2023;170:1-27. doi: 10.1016/bs.irn.2023.08.001. Epub 2023 Aug 25.
4
Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A Adenosine Receptor Useful in Neurodegenerative Disorders.双重靶向蛋白激酶 CK1δ 和 A 腺苷受体的拮抗剂在神经退行性疾病中的应用。
Molecules. 2023 Jun 14;28(12):4762. doi: 10.3390/molecules28124762.
5
Caffeine for Prevention of Alzheimer's Disease: Is the A Adenosine Receptor Its Target?咖啡因预防阿尔茨海默病：A 腺苷受体是其靶点吗？
Biomolecules. 2023 Jun 8;13(6):967. doi: 10.3390/biom13060967.
6
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications.腺苷受体变构调节剂的最新进展及其治疗应用
Front Pharmacol. 2022 Oct 5;13:1030895. doi: 10.3389/fphar.2022.1030895. eCollection 2022.
7
Pathophysiological Role and Medicinal Chemistry of A Adenosine Receptor Antagonists in Alzheimer's Disease.A 腺苷受体拮抗剂在阿尔茨海默病中的病理生理作用和药物化学。
Molecules. 2022 Apr 21;27(9):2680. doi: 10.3390/molecules27092680.
8
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.神经精神疾病中的腺苷受体：神经传递的精细调节剂和潜在治疗靶点。
Int J Mol Sci. 2022 Jan 22;23(3):1219. doi: 10.3390/ijms23031219.
9
Molecular Integration in Adenosine Heteroreceptor Complexes Through Allosteric and De-Phosphorylation (STEP) Mechanisms and its Role in Brain Disease.通过变构和去磷酸化（STEP）机制实现腺苷异源受体复合物中的分子整合及其在脑部疾病中的作用
Front Pharmacol. 2022 Jan 5;12:781381. doi: 10.3389/fphar.2021.781381. eCollection 2021.
10
Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study.较高的咖啡摄入量与126个月内较慢的认知衰退和较少的脑β-淀粉样蛋白积累相关：来自澳大利亚成像、生物标志物和生活方式研究的数据。
Front Aging Neurosci. 2021 Nov 19;13:744872. doi: 10.3389/fnagi.2021.744872. eCollection 2021.

本文引用的文献

1
Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.淀粉样蛋白 PET 和 F-FDG-PET 在阿尔茨海默病和其他痴呆症的诊断研究中的应用。
Lancet Neurol. 2020 Nov;19(11):951-962. doi: 10.1016/S1474-4422(20)30314-8.
2
Alzheimer's Disease, Inflammation, and the Role of Antioxidants.阿尔茨海默病、炎症与抗氧化剂的作用
J Alzheimers Dis Rep. 2020 Jun 16;4(1):175-183. doi: 10.3233/ADR-200171.
3
Adenosine A receptor antagonists: from caffeine to selective non-xanthines.腺苷 A 受体拮抗剂：从咖啡因到选择性非黄嘌呤类。
Br J Pharmacol. 2022 Jul;179(14):3496-3511. doi: 10.1111/bph.15103. Epub 2020 Jun 19.
4
Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS.嘌呤能机制对健康和疾病中枢神经系统中小胶质细胞功能的调节。
Cells. 2020 Apr 29;9(5):1108. doi: 10.3390/cells9051108.
5
Adenosine A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease.腺苷 A 受体拮抗剂影响 NMDA 谷氨酸受体功能。有潜力用于治疗阿尔茨海默病中的神经退行性变。
Cells. 2020 Apr 26;9(5):1075. doi: 10.3390/cells9051075.
6
Association of Coffee, Decaffeinated Coffee and Caffeine Intake from Coffee with Cognitive Performance in Older Adults: National Health and Nutrition Examination Survey (NHANES) 2011-2014.咖啡、脱咖啡因咖啡和咖啡因摄入量与老年人认知表现的关联：2011-2014 年国家健康和营养调查（NHANES）。
Nutrients. 2020 Mar 20;12(3):840. doi: 10.3390/nu12030840.
7
The belated US FDA approval of the adenosine A receptor antagonist istradefylline for treatment of Parkinson's disease.美国食品和药物管理局（FDA）姗姗来迟，批准腺苷 A 受体拮抗剂伊曲茶碱用于治疗帕金森病。
Purinergic Signal. 2020 Jun;16(2):167-174. doi: 10.1007/s11302-020-09694-2. Epub 2020 Mar 31.
8
Influence of metabolic syndrome on cerebral perfusion and cognition.代谢综合征对脑灌注和认知的影响。
Neurobiol Dis. 2020 Apr;137:104756. doi: 10.1016/j.nbd.2020.104756. Epub 2020 Jan 21.
9
Advances and considerations in AD tau-targeted immunotherapy.AD tau 靶向免疫疗法的进展与思考。
Neurobiol Dis. 2020 Feb;134:104707. doi: 10.1016/j.nbd.2019.104707. Epub 2019 Dec 10.
10
NLRP3 inflammasome activation drives tau pathology.NLRP3 炎性小体激活驱动 tau 病理。
Nature. 2019 Nov;575(7784):669-673. doi: 10.1038/s41586-019-1769-z. Epub 2019 Nov 20.